Cancer Antibody Drug Conjugates Treatment Market USD 50 Billion Opportunity Says Kuick Research. Delhi, July 11, 2025 (GLOBE ...

The company announced promising results from its LOTIS-7 Phase 1b trial, where the combination of ZYNLONTA and glofitamab showed a 93.3% overall response rate in patients with relapsed or refractory ...

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ...

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML) ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from a Phase 2 multicenter investigator ...

The study evaluated 41 patients for safety and 30 for efficacy across two ZYNLONTA dose levels (120 μg/kg and 150 μg/kg) in combination with glofitamab.

Discover ADC Therapeutics' Q1 2025 earnings insights, with strong progress in ZYNLONTA trials, high response rates, and a solid cash runway.

Management estimated ZYNLONTA’s peak revenue in the U.S. at $600 million to $1 billion, contingent on regulatory approval and compendia listing. For LOTIS-5, updated data are expected by the end ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy. About ADC Therapeutics ...

ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of ...